PURPOSE: Homologous DNA repair-deficient (HRD) ovarian cancers (OCs), including those with BRCA1/2 mutations, have higher levels of genetic instability, potentially resulting in higher immunogenicity, and have been suggested to respond better to immune checkpoint inhibitors (ICIs) than homologous DNA repair-proficient OCs. However, clinical evidence is lacking. The study aimed to evaluate the associations between BRCA1/2 mutations, HRD, and other genomic parameters and response to ICIs and survival in OC. METHODS: This is a single-institution retrospective analysis of women with recurrent OC treated with ICIs. BRCA1/2 mutation status and clinicopathologic variables were abstracted from the medical records. Targeted and whole-exome sequencing data available for a subset of patients were used to assess tumor mutational burden (TMB), HRD, and fraction of genome altered (FGA). ICI response was defined as lack of disease progression for ≥ 24 weeks. Associations of BRCA1/2 status and genomic alterations with progression-free survival (PFS) and overall survival (OS) were determined using Cox proportional hazards models. RESULTS: Of the 143 women treated with ICIs, 134 had known BRCA1/2 mutation status. Deleterious germline or somatic BRCA1/2 mutations were present in 31 women (24%). There was no association between presence of BRCA1/2 mutations and response (P = .796) or survival. Genomic analysis in 73 women found no association between TMB (P = .344) or HRD (P = .222) and response, PFS, or OS. There were also no significant differences in somatic genetic alterations between responders and nonresponders. High FGA was associated with an improvement in PFS (P = .014) and OS (P = .01). CONCLUSION: TMB, BRCA1/2 mutations, and HRD are not associated with response or survival, cautioning against their use as selection criteria for ICI in recurrent OC. FGA should be investigated further as a biomarker of response to immunotherapy in OC.
PURPOSE: Homologous DNA repair-deficient (HRD) ovarian cancers (OCs), including those with BRCA1/2 mutations, have higher levels of genetic instability, potentially resulting in higher immunogenicity, and have been suggested to respond better to immune checkpoint inhibitors (ICIs) than homologous DNA repair-proficient OCs. However, clinical evidence is lacking. The study aimed to evaluate the associations between BRCA1/2 mutations, HRD, and other genomic parameters and response to ICIs and survival in OC. METHODS: This is a single-institution retrospective analysis of women with recurrent OC treated with ICIs. BRCA1/2 mutation status and clinicopathologic variables were abstracted from the medical records. Targeted and whole-exome sequencing data available for a subset of patients were used to assess tumor mutational burden (TMB), HRD, and fraction of genome altered (FGA). ICI response was defined as lack of disease progression for ≥ 24 weeks. Associations of BRCA1/2 status and genomic alterations with progression-free survival (PFS) and overall survival (OS) were determined using Cox proportional hazards models. RESULTS: Of the 143 women treated with ICIs, 134 had known BRCA1/2 mutation status. Deleterious germline or somatic BRCA1/2 mutations were present in 31 women (24%). There was no association between presence of BRCA1/2 mutations and response (P = .796) or survival. Genomic analysis in 73 women found no association between TMB (P = .344) or HRD (P = .222) and response, PFS, or OS. There were also no significant differences in somatic genetic alterations between responders and nonresponders. High FGA was associated with an improvement in PFS (P = .014) and OS (P = .01). CONCLUSION:TMB, BRCA1/2 mutations, and HRD are not associated with response or survival, cautioning against their use as selection criteria for ICI in recurrent OC. FGA should be investigated further as a biomarker of response to immunotherapy in OC.
Authors: Daniel C Koboldt; Qunyuan Zhang; David E Larson; Dong Shen; Michael D McLellan; Ling Lin; Christopher A Miller; Elaine R Mardis; Li Ding; Richard K Wilson Journal: Genome Res Date: 2012-02-02 Impact factor: 9.043
Authors: Kent W Mouw; Michael S Goldberg; Panagiotis A Konstantinopoulos; Alan D D'Andrea Journal: Cancer Discov Date: 2017-06-19 Impact factor: 39.397
Authors: Fresia Pareja; Ju Youn Lee; David N Brown; Salvatore Piscuoglio; Rodrigo Gularte-Mérida; Pier Selenica; Arnaud Da Cruz Paula; Sasi Arunachalam; Rahul Kumar; Felipe C Geyer; Catarina Silveira; Edaise M da Silva; Anqi Li; Caterina Marchiò; Charlotte K Y Ng; Odette Mariani; Laetitia Fuhrmann; Hannah Y Wen; Larry Norton; Anne Vincent-Salomon; Edi Brogi; Jorge S Reis-Filho; Britta Weigelt Journal: J Natl Cancer Inst Date: 2019-07-01 Impact factor: 13.506
Authors: Panagiotis A Konstantinopoulos; Steven Waggoner; Gregory A Vidal; Monica Mita; John W Moroney; Robert Holloway; Linda Van Le; Jasgit C Sachdev; Eloise Chapman-Davis; Gerardo Colon-Otero; Richard T Penson; Ursula A Matulonis; Young Bae Kim; Kathleen N Moore; Elizabeth M Swisher; Anniina Färkkilä; Alan D'Andrea; Erica Stringer-Reasor; Jing Wang; Nathan Buerstatte; Sujata Arora; Julie R Graham; Dmitri Bobilev; Bruce J Dezube; Pamela Munster Journal: JAMA Oncol Date: 2019-08-01 Impact factor: 31.777
Authors: Takehito Shukuya; Keita Mori; Joseph M Amann; Erin M Bertino; Gregory A Otterson; Peter G Shields; Satoshi Morita; David P Carbone Journal: J Thorac Oncol Date: 2016-08-03 Impact factor: 15.609
Authors: Andrea M Marquard; Aron C Eklund; Tejal Joshi; Marcin Krzystanek; Francesco Favero; Zhigang C Wang; Andrea L Richardson; Daniel P Silver; Zoltan Szallasi; Nicolai J Birkbak Journal: Biomark Res Date: 2015-05-01
Authors: Nicholas McGranahan; Andrew J S Furness; Rachel Rosenthal; Sofie Ramskov; Rikke Lyngaa; Sunil Kumar Saini; Mariam Jamal-Hanjani; Gareth A Wilson; Nicolai J Birkbak; Crispin T Hiley; Thomas B K Watkins; Seema Shafi; Nirupa Murugaesu; Richard Mitter; Ayse U Akarca; Joseph Linares; Teresa Marafioti; Jake Y Henry; Eliezer M Van Allen; Diana Miao; Bastian Schilling; Dirk Schadendorf; Levi A Garraway; Vladimir Makarov; Naiyer A Rizvi; Alexandra Snyder; Matthew D Hellmann; Taha Merghoub; Jedd D Wolchok; Sachet A Shukla; Catherine J Wu; Karl S Peggs; Timothy A Chan; Sine R Hadrup; Sergio A Quezada; Charles Swanton Journal: Science Date: 2016-03-03 Impact factor: 47.728
Authors: Kristian Cibulskis; Michael S Lawrence; Scott L Carter; Andrey Sivachenko; David Jaffe; Carrie Sougnez; Stacey Gabriel; Matthew Meyerson; Eric S Lander; Gad Getz Journal: Nat Biotechnol Date: 2013-02-10 Impact factor: 54.908
Authors: Koji Matsuo; Samantha E Spragg; Marcia A Ciccone; Erin A Blake; Charité Ricker; Huyen Q Pham; Lynda D Roman Journal: Gynecol Oncol Rep Date: 2018-06-20
Authors: Giuseppe Narzisi; André Corvelo; Kanika Arora; Ewa A Bergmann; Minita Shah; Rajeeva Musunuri; Anne-Katrin Emde; Nicolas Robine; Vladimir Vacic; Michael C Zody Journal: Commun Biol Date: 2018-03-22
Authors: Adam A Kraya; Kara N Maxwell; Monika A Eiva; Bradley Wubbenhorst; John Pluta; Michael Feldman; Anupma Nayak; Daniel J Powell; Susan M Domchek; Robert H Vonderheide; Katherine L Nathanson Journal: JCO Precis Oncol Date: 2022-02
Authors: Jason A Konner; Dmitriy Zamarin; Tiffany Y Sia; Beryl Manning-Geist; Sushmita Gordhandas; Rajmohan Murali; Antonio Marra; Ying L Liu; Claire F Friedman; Travis J Hollmann; Oliver Zivanovic; Dennis S Chi; Britta Weigelt Journal: Int J Gynecol Cancer Date: 2022-08-01 Impact factor: 4.661
Authors: Lisa Kinget; Oliver Bechter; Kevin Punie; Philip R Debruyne; Hilde Brems; Paul Clement; Eduard Roussel; Yannick Van Herck; Maarten Albersen; Marcella Baldewijns; Patrick Schöffski; Benoit Beuselinck Journal: Curr Oncol Date: 2021-08-24 Impact factor: 3.677
Authors: Stella V Paffenholz; Camilla Salvagno; Yu-Jui Ho; Matthew Limjoco; Timour Baslan; Sha Tian; Amanda Kulick; Elisa de Stanchina; John E Wilkinson; Francisco M Barriga; Dmitriy Zamarin; Juan R Cubillos-Ruiz; Josef Leibold; Scott W Lowe Journal: Proc Natl Acad Sci U S A Date: 2022-02-01 Impact factor: 11.205